Exane Derivatives’s Host Hotels & Resorts HST Stock Holding History

Exane Derivatives’s Portfolio HST Stock Details HST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,847	Closed	-$198K	–	671
2019 Q2	$198K	Buy	+10,847	New	+$204K	0.03%	272
2016 Q2	–	Sell	-2,794	Closed	-$46.7K	–	589
2016 Q1	$46.7K	Buy	+2,794	New	+$42K	0.01%	324

Other funds holding HST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Exane Derivatives's HST Position: Q3 2019 in Review

Exane Derivatives sold out of Host Hotels & Resorts (HST) in Q3 2019, closing a stake of 10,847 shares — an estimated $198K sold.

Exane Derivatives first reported a position in HST in Q1 2016 and held it in 2 quarters. The position peaked at $198K in Q2 2019. 542 funds tracked by Wall St. Rank hold HST as of Q3 2019.

Exane Derivatives reported no remaining Host Hotels & Resorts position as of Q3 2019 after selling out during the quarter.
Exane Derivatives sold 10,847 Host Hotels & Resorts shares in Q3 2019, an estimated $198K.
Exane Derivatives first reported a position in Host Hotels & Resorts in Q1 2016 and held it in 2 quarters.
Exane Derivatives's Host Hotels & Resorts position peaked at $198K in Q2 2019.
542 funds tracked by Wall St. Rank held Host Hotels & Resorts as of Q3 2019.

Based on Exane Derivatives's 13F filing for Q3 2019, filed 15 Oct 2019.